1024 / 1851
Hybrid study:
SBRT with concurrent chemoradiation
Toxicity profile using CTCAE v4
DVH parameters
Conclusions
A Hybrid treatment of SBRT of the primary tumor
combined with fractionated radiotherapy on the
lymph nodes with concurrent chemotherapy is
feasible.
This phase I trial (NCT01933568) is currently
accruing and no unexpected toxicity has been
observed thus far.
Courtesy of J. Belderbos